Paul Rivard - Net Worth and Insider Trading

Paul Rivard Net Worth

The estimated net worth of Paul Rivard is at least $16,666 dollars as of 2024-11-13. Paul Rivard is the Chief Legal Officer of TNF Pharmaceuticals Inc and owns about 13,333 shares of TNF Pharmaceuticals Inc (TNFA) stock worth over $16,666. Details can be seen in Paul Rivard's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Paul Rivard has not made any transactions after 2023-08-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Paul Rivard

To

Paul Rivard Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Paul Rivard owns 1 companies in total, including TNF Pharmaceuticals Inc (TNFA) .

Click here to see the complete history of Paul Rivard’s form 4 insider trades.

Insider Ownership Summary of Paul Rivard

Ticker Comapny Transaction Date Type of Owner
TNFA TNF Pharmaceuticals Inc 2023-08-24 EVP of Operations & GC

Paul Rivard Latest Holdings Summary

Paul Rivard currently owns a total of 1 stock. Paul Rivard owns 13,333 shares of TNF Pharmaceuticals Inc (TNFA) as of August 24, 2023, with a value of $16,666.

Latest Holdings of Paul Rivard

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TNFA TNF Pharmaceuticals Inc 2023-08-24 13,333 1.25 16,666

Holding Weightings of Paul Rivard


Paul Rivard Form 4 Trading Tracker

According to the SEC Form 4 filings, Paul Rivard has made a total of 4 transactions in TNF Pharmaceuticals Inc (TNFA) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in TNF Pharmaceuticals Inc is the acquisition of 5,000 shares on August 24, 2023, which cost Paul Rivard around $166,500.

Insider Trading History of Paul Rivard

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Paul Rivard Trading Performance

GuruFocus tracks the stock performance after each of Paul Rivard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul Rivard is -38.04%. GuruFocus also compares Paul Rivard's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul Rivard within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Paul Rivard's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Paul Rivard

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -28.76 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -28.65 LIMIT LIMIT LIMIT LIMIT LIMIT

Paul Rivard Ownership Network

Ownership Network List of Paul Rivard

No Data

Ownership Network Relation of Paul Rivard

Insider Network Chart

Paul Rivard Owned Company Details

What does TNF Pharmaceuticals Inc do?

Who are the key executives at TNF Pharmaceuticals Inc?

Paul Rivard is the EVP of Operations & GC of TNF Pharmaceuticals Inc. Other key executives at TNF Pharmaceuticals Inc include director & President & Chief Med. Officer Chapman Christopher C Jr , Chief Scientific Officer Adam Kaplin , and 10 percent owner Caroline C Williams .

TNF Pharmaceuticals Inc (TNFA) Insider Trades Summary

Over the past 18 months, Paul Rivard made 2 insider transaction in TNF Pharmaceuticals Inc (TNFA) with a net purchase of 175,000.

In summary, during the past 3 months, insiders sold 0 shares of TNF Pharmaceuticals Inc (TNFA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TNF Pharmaceuticals Inc (TNFA) were sold and 5,833 shares were bought by its insiders, resulting in a net purchase of 5,833 shares.

TNF Pharmaceuticals Inc (TNFA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

TNF Pharmaceuticals Inc Insider Transactions

No Available Data

Paul Rivard Mailing Address

Above is the net worth, insider trading, and ownership report for Paul Rivard. You might contact Paul Rivard via mailing address: C/o Akers Biosciences, Inc., 1185 Avenue Of The Americas, 3rd Floor, New York Ny 10036.